Exercise, Aromatase Inhibitors, Quality Of Life, And Breast Cancer by Baglia, Michelle
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses School of Public Health
January 2012




Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation






EXERCISE, AROMATASE INHIBITORS, 










A Thesis Presented to 




In Candidacy for the Degree of  






Purpose: We conducted a randomized controlled trial of 39 breast cancer survivors who were 
currently taking aromatase inhibitors and experiencing painful side effects. The purpose of this 
study was to investigate the role of a 6-month exercise intervention on (1) endocrine-related 
quality of life and (2) overall quality of life. Methods: Eligible women completed self-
administered questionnaires at baseline and 6 months including the FACT-B +ES to assess 
quality of life. The participants were randomized to either an exercise intervention group that 
met twice weekly with a personal trainer or usual care. T-tests and χ
2
 analyses were used to 
assess differences in endocrine-related quality of life over the 6-month intervention period as 
well as overall quality of life. The subscales of the FACT-B were examined independently using 
t-tests. Results: The average baseline endocrine-related QOL score was 56.2 for all participants 
in the study. The average score did not differ by treatment group (p=0.81). Mean 6-month 
changes from baseline for exercisers for the full QOL endocrine subscale was +3.3 compared to 
usual care (+1.8). The difference between the two groups was not statistically significant 
(p=0.32). A significant difference between the exercisers and usual care group for favorable 
changes in joint pain was observed (p-value = 0.014). A moderately significant effect was also 
seen for favorable changes on bloating in exercisers as compared to the usual care group (p-value 
= 0.055). Conclusion: In this study, aerobic exercise, such as treadmill walking, and strength 
training were associated with increases in endocrine-related quality of life. In particular, the 
intervention was associated with significant decreases in joint pain. These results are 
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Breast cancer is the leading cancer diagnosis in women in the United States. Of those 
diagnosed, approximately 70% present with estrogen receptor positive tumors[1]. Aromatase 
inhibitors (AIs) have been shown to be the most effective hormonal/endocrine therapy treatment 
in estrogen receptor-positive breast cancer, and are therefore considered standard of care and 
generally prescribed for postmenopausal women diagnosed with estrogen-receptor positive 
breast cancer[1]. Because of their physiological action mechanism, AIs cause lowered levels of 
estrogen which are associated with menopausal symptoms, such as hot flashes and night sweats, 
which in turn may impair quality of life[2]. Given the effectiveness of AIs in reducing both risk 
of recurrence and breast cancer death, and therefore the strong recommendation by clinicians for 
their patients to take AIs, understanding how to reduce the severity of AI related side effects is 
necessary. 
Numerous studies have examined the relationship between physical activity and well-
being, depression, anxiety, physical and emotional functioning, overall quality of life, and other 
psychosocial factors in breast cancer survivors[3-4]. Exercise has been shown to improve overall 
quality of life in women diagnosed with breast cancer[5-7]. However, there have not been any 
studies to date that have explored the impact of exercise on side effects of AIs and on endocrine-
related QOL in women taking an AI for early stage breast cancer. QOL in cancer survivors is 
commonly measured via the Functional Assessment of Cancer Therapy (FACT) questionnaire, 
with subscales developed for particular cancers, e.g., FACT-Breast (FACT-B) for breast cancer. 
Furthermore, an endocrine-subscale was recently developed and validated for use with the 
FACT-B, the FACT-B endocrine subscale or FACT-B-ES, and is comprised of 18 questions[3]. 
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An additional question was added to assess joint pain[8], as this is a common side effect of AIs, 
making a 19 question endocrine subscale (Table 1). This scale has high validity and reliability 
making it appropriate for measuring endocrine symptoms in women diagnosed with breast 
cancer taking AIs[3].  
The purpose of this study, entitled the Hormones and Physical Exercise (HOPE) Study, 
was to examine, in 180 postmenopausal breast cancer survivors who have been taking an AI for 
at least 6 months and reporting at least mild arthralgias (i.e., joint pain), the effect of a 
randomized controlled exercise intervention vs. usual care on endocrine-related QOL. We 
hypothesized that the exercise group would show improved endocrine-related QOL measures as 
compared to the usual care group. This is a preliminary analysis on the first 39 women who 
completed 6 months of the intervention. 
Materials and Methods 
Study Population 
Women diagnosed with Stage I-IIIC breast cancer were eligible for the study (see Table 
2). AIs are not approved for ductal carcinoma in situ (DCIS), therefore women diagnosed with 
DCIS were not eligible. Participants must also have been taking an AI for at least 6 months and 
be currently experiencing side effects of the medication (i.e., at least mild arthralgia, defined as > 
3 on the Brief Pain Inventory (BPI) Short Form Questionnaire[9]).  
To observe a maximal effect from the exercise intervention, only women reporting less 
than 90 min/wk of moderate-to-vigorous intensity aerobic exercise and no strength training in the 
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previous year, as well as low fitness level (< 25 ml/kg/min, as measured by VO2 max), were 
eligible to participate. Because a majority of the US population including breast cancer survivors 
are physically inactive, we anticipated excluding < 25% of the population based on this 
criteria[10].  
Recruitment 
We used the Rapid Case Ascertainment (RCA) Shared Resource Service of the Yale 
Cancer Center to obtain names of women diagnosed with hormone receptor positive breast 
cancer and treated at one of four hospitals in CT: Smilow Cancer Hospital at Yale-New Haven, 
St. Raphael’s Hospital, Bridgeport Hospital, and Greenwich Hospital. The RCA provides the PI 
with potential participants’ names and their physician’s names. Physicians were contacted first 
for permission to contact the participant. If approved by the physician, we then mailed an 
invitation letter to the participant, describing the study and telling her that the study manager 
would call her within a week to tell her about the study and to solicit her interest and eligibility 
(i.e., screening telephone call). If the participant was eligible and interested, she was scheduled 
for a baseline visit.  
Between April 1, 2010 and October 1, 2011, we completed 555 screening telephone calls. 
Of the 555 women screened, 25% were ineligible because of discontinuation of AI treatment 
because of side effects or choosing not to take AIs primarily because of potential side effects, 
another 38% were ineligible for various reasons, and 25% were not interested. The remaining 
12% (n = 65) were enrolled in the study and subsequently randomized to the intervention or 
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usual care group. Of these 65 women, 39 completed six months of the study as of March 1, 2012, 
and are included in the analyses.  
Data Collection 
Data collection for this study involved a screening phone call, clinic visits at baseline and 
6-months, and 6 months of the exercise intervention or usual care. Participants completed a QOL 
questionnaire, a 7-day daily activity log, a physical activity questionnaire, and attended a clinic 
visit for physical measurements at baseline and 6 months.  
Randomization 
Participants were randomized to either the exercise group or usual care with equal 
probability, with blocking on whether taking a bisphosphonate (Y/N) and whether pain started 
after initiating the AI (Y/N). Those women randomized to the exercise group were scheduled for 
their first supervised exercise training session at a local health club immediately. Women 
randomized to the usual care group were contacted by a trained health professional on a monthly 
basis to discuss relevant health topics so as to maintain study compliance.  
Measures 
Demographics and medical history. Self-administered questionnaires were completed by the 
participants for the baseline visit to collect this information. 
Endocrine-related QOL. QOL was measured by self-report at baseline and 6 month clinic visits 
and reviewed by research staff. QOL was measured using the Functional Assessment of Cancer 
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Therapy-Breast (FACT-B) questionnaire (version 3), together with the endocrine symptom 
subscale (ES) questionnaire (FACT-B+ES)[11]. The FACT-B is a 36-item questionnaire with six 
subscales assessing physical, social, emotional, and functional well-being, and additional 
concerns more specific to women with breast cancer (Appendix 1). The ES was designed for use 
with the FACT-B and comprises 19 items (e.g., hot flashes, night sweats, weight gain, joint pain 
(see Table 1)). Participants indicated how true a statement had been for them over the past 7 days 
using a 5-point scale ranging from 0 (none at all) to 4 (very much). All items received equal 
weighting for the analysis.  
Physical activity. At baseline and 6-months, participants completed a 7-day physical activity log 
(PAL)[12] and an interviewer-administered physical activity questionnaire[13] to assess physical 
activity over the past 6 months. For the PAL, women recorded the type and duration of any 
recreational activity performed on each day. Hours per week spent in moderate-to-vigorous 
intensity aerobic activity were determined using Ainsworth’s Compendium of Physical 
Activities[14]. 
Anthropometrics. Height and weight were measured at baseline and 6 months and BMI was 
calculated. Participants were weighed in light indoor clothing, without shoes, rounding up to the 
nearest 0.1 kg; height was measured in a standard manner, without shoes, using a stadiometer, 
rounding up to the nearest 0.1 cm. All measures were performed and recorded twice in 




The exercise intervention group received social and behavioral support and research staff 
contact time to encourage them to increase their exercise level to include twice weekly strength-
training sessions and 150 min of aerobic exercise per week (e.g., three 50-min aerobic exercise 
sessions or five 30-min sessions) over 6 months. The trainer and participant(s) met at a local gym 
designated by the study weekly during designated times.  
Strength Training Sessions: Each strength training session was ~45 minutes. Six common 
strength-training exercises were performed using variable resistance machines (for muscles of 
the chest, back, shoulders, quadriceps, hamstrings, and gluteals, as well as biceps and triceps). 
We used the protocol developed by Katie Schmitz and colleagues. Their protocol was used in the 
Physical Activity and Lymphedema (PAL) trial of strength training on lymphedema in breast 
cancer survivors[15-16].  
Aerobic Exercise Intervention: The participants were also required to do aerobic exercise for a total 
of 150 min/week (the current PA recommendation[17]), whether it be at the health club or in their 
neighborhood. Participants gradually worked up to exercising 150 min per week within the first 
two months.  
Recording of Strength and Walking Exercise Sessions: Following each strength and aerobic 
exercise session, subjects completed a physical activity log. The logs were submitted weekly to the 
Exercise Trainer, who reviewed the log in the presence of the participant. If two days of strength 
training and 150 min/wk of aerobic exercise were not performed in the previous week, the trainer and 
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participant discussed the barriers experienced by the participant which prevented the participant from 
fulfilling the prescribed exercise regimen.  
Usual Care 
Immediately after randomization, participants in the usual care group were provided 
written information that emphasized the importance of a healthy lifestyle. Participants were 
encouraged to follow the NCI and ACS physical activity guidelines. Each month, women 
randomized to usual care were contacted by a trained health professional to discuss health 
education topics relevant to breast cancer survivors. Health education sessions that focused on 
issues relevant to women taking AIs, and breast cancer survivors in general, were included.  
Statistical Analysis 
Participants were grouped according to the intention-to-treat procedure in which all 
participants were grouped according to their intervention assignment at randomization regardless 
of adherence. A sample size of 39 women was used at the time of this preliminary analysis 
because this was the number of participants who had completed 6-months of the intervention as 
of March 1, 2012. T-tests and χ
2
 analyses were used to assess between-group differences at 
baseline. The endocrine-related QOL score was calculated by subtracting each individual answer 
for each question from 4 and totaling the sum from the 19 questions with a total possible score of 
0 to 76, with higher scores indicating better QOL. The total summed scores for the exercise and 
usual care groups were then compared using a t-test. A t-test was also used to test for significant 
within group differences between baseline and 6 months. Differences in response between the 
groups on a per question basis were also examined using t-tests. Changes in endocrine-related 
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QOL by adherence to the intervention were examined in the exercise group only. Changes in the 
FACT-B by intervention group were also examined by scoring and summing the FACT-B in a 
similar manner to the endocrine subscale where answers to negative questions were subtracted 
from 4 and positive questions were scored as the answer on the number scale given. The 
individual subscales of the FACT-B (physical (7 items, possible score range 0-28 points), social 
(7 items, possible score range 0-28 points), emotional (6 items, possible score 0-24 points), 
functional (7 items, possible score range 0-28 points), and breast cancer (9 items, possible score 
range 0-36 points) subscales) were scored and examined separately. Aggregate scores for the 
FACT-B (which included the physical, social, emotional, functional, and breast cancer 
subscales) and FACT-B +ES were calculated as well (possible score range 0-144 and 0-220, 
respectively).  T-tests were used to assess differences between intervention groups at baseline, 6 
months, and changes over the intervention period for each subscale separately as well as the 
aggregate scores for the FACT-B and FACT-B + ES. Additionally, regression analysis was used 
to build a model to determine if there were any baseline characteristics associated with 
endocrine-related QOL at baseline. Statistical analyses were performed using SAS software 
(version 9.2; SAS Institute Inc, Cary, NC).  
Results 
Baseline characteristics 
Baseline demographic and physiologic data in the exercise and usual care groups were 
similar (Table 2). The average age of study participants was 62.7 years. The majority (87.2%) of 
participants were non-Hispanic white. The participants were, on average, overweight at baseline 
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(average BMI 28.8) and averaged 62.9 minutes per week of recreational exercise on the daily 
activity log. Average time since breast cancer diagnosis was 2.7 years. The average length of 
time participants had been taking an AI was 2.1 years.  
Change in physical activity levels and adherence to the exercise intervention 
At baseline, the participants in both groups averaged 71.6 minutes per week of exercise 
and no strength training over the previous six months as measured by the PAQ. On average, 
exercisers increased their weekly activity, as measured by the PAQ, by 195.5 minutes per week 
at six months while the usual care group increased their weekly activity by 39.6 minutes per 
week (p=0.0008). Exercisers increased their weekly strength training by 58.6 minutes compared 
to controls who increased strength training by 7.4 minutes per week (p<.0001). 
When examining adherence to the exercise intervention among women randomized to 
exercise, as measured by the 7-day Physical Activity Log, on average, exercisers completed 135 
minutes per week of moderate-to-vigorous intensity exercise over the 6 month study period, and 
47.2% reported participating in at least 150 min/wk of exercise. 57.1% reported participating in 
120 min/wk of exercise (80% of the goal). Attendance to the twice-weekly in-person/supervised 
exercise sessions was 83.1%, with 81.0% of the exercisers attending at least 70% of the gym 
sessions and 61.9% attending at least 80% of the gym sessions (Table 3).  
Baseline endocrine-related QOL by treatment group 
The average baseline endocrine-related QOL score was 56.2 for all participants in the 
study. This score was out of 76 possible points with a higher score being indicative of a higher 
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measure of quality of life. The average score did not differ by treatment group (p=0.81). Each 
question was broken down individually to detect differences between the treatment groups by 
question. There were no statistical differences between the groups by question at baseline (all 
p>0.05). The association between baseline characteristics and baseline endocrine-related QOL 
was examined. Only age was associated with the measure—as age increased by one year the 
endocrine-related QOL score increased by 0.74 points.  
Effect of exercise vs. usual care on endocrine-related QOL 
Mean 6-month changes from baseline for exercisers for the full QOL endocrine subscale 
was +3.3 compared to usual care (+1.8) (Table 4). The difference between the two groups was 
not statistically significant (p=0.32). The questions were broken down into four groups by 
symptom type: vasomotor (hot flashes, cold sweats, night sweats), neuropsychological 
(lightheaded/dizzy, headaches, mood swings, irritableness), gastrointestinal (weight gain, 
vomiting, diarrhea, bloating), and gynecological (vaginal discharge, itching, bleeding, dryness, 
discomfort during intercourse, loss of interest in sex, breast tenderness)—so as to look for 
differences between groups for different types of symptoms. No significant differences were 
detected between the two groups. When each item on the endocrine subscale was evaluated 
independently, a significant difference between the exercisers and usual care group for favorable 
changes in joint pain was observed (p-value = 0.014). A moderately significant effect was also 
seen for favorable changes on bloating in exercisers as compared to the usual care group (p-value 
= 0.055). See Table 5 for complete results. 
Effect of exercise on endocrine-related QOL stratified by potential effect modifiers 
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Several variables were examined as potential effect modifiers on the change in endocrine-
related QOL including age, BMI, and time on AI. No effect modification was seen in this 
sample. 
Effect of exercise on endocrine-related QOL stratified by adherence 
Participants were classified as high adherers if they attended more than 80% of gym 
sessions or averaged at least 150 minutes of recreational exercise per week throughout the 6-
month intervention. The effect of adherence on endocrine-related quality of life was not 
significant for percent of gym sessions attended, minutes per week of recreational exercise, or a 
combination of the two measures. These findings remained even when we defined high adherers 
differently, e.g., 70% of gym sessions or the median value. 
Effect of exercise on endocrine-related QOL stratified by weight loss 
 On average, participants in the exercise group lost 1.76 pounds over the 6-month 
intervention period compared with 0.40 pounds lost among participants in the control group. 
Exercisers who lost weight had higher session attendance than those exercisers who maintained 
weight (87.1% vs. 78.6%, p=0.12) but reported similar average minutes per week spent doing 
moderate-to-vigorous aerobic exercise (140.5 vs. 158.9, p=0.51). When exercisers were stratified 
by weight loss vs. maintaining weight, there was a significant difference in changes in endocrine-
related QOL. Exercisers who lost weight averaged a 5.4 increase in endocrine-related QOL 
whereas exercisers who maintained their weight averaged a 1.0 increase (p=0.049) (Table 6).  
Effect of exercise vs. usual care on overall QOL measured by FACT-B 
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There were no significant differences at baseline between the intervention and usual care 
groups for overall FACT-B scores or any of the subscales (physical, social, emotional, 
functional, and breast cancer) (Table 3). Mean 6-month changes from baseline for exercisers for 
the FACT-B were +10.4 compared to usual care (+3.6). The difference between the two groups 
was moderately significant (p=0.097). When each subscale was examined separately there were 
significant differences in changes over 6-months for the physical well-being and social/family 
well-being subscales. Exercisers increased by 2.5 points on the physical well-being scale and 2.0 
points on the social/family well-being scale compared to 0.1 and -0.3, respectively, for the usual 
care group (p=0.034, p=0.037, respectively). A moderately significant effect was detected for the 
entire FACT-B-ES 6-month changes between the exercisers and usual care group (p=0.081). The 
full list of group means and p-values for between group differences for the FACT-B and 
subscales can be found in Table 4. 
Discussion 
In this study, aerobic exercise, such as treadmill walking, and strength training were 
associated with increases in endocrine-related quality of life. In particular, the intervention was 
associated with significant decreases in joint pain. As joint pain is a significant concern for breast 
cancer survivors taking AIs, this finding is of particular importance. Adverse events associated 
with taking AIs are the main reason for treatment discontinuation[18]. These results are 




Due to adverse symptoms and treatment, cancer survivors may have difficulty changing 
physical activity levels[19]. The breast cancer survivors in this study were all experiencing pain 
associated with taking an AI for cancer treatment. This intervention was effective in getting these 
breast cancer survivors to increase their exercise levels indicating that even survivors 
experiencing moderate to severe adverse treatment-associated symptoms can increase their 
exercise levels. Furthermore, this increase in physical activity can alleviate pain associated with 
AI use.  
Age was significantly associated with increased baseline endocrine-related QOL scores. 
This may be due to older women being less bothered by endocrine therapy side effects because 
of expected age-related declines. Younger women may feel that they are more limited in their 
abilities or have poorer overall health than their peers compared to older women which may 
influence the impact of endocrine therapy on quality of life. Other studies have shown that older 
breast cancer survivors are less affected by treatment over a variety of measures including 
health-related QOL[20-21]. 
The improvement in endocrine-related QOL observed among the exercise group was also 
observed among the usual care group, yet at a lower rate of improvement; thus, the between 
group differences in change in endocrine-related QOL was not significant. It is possible that this 
amount of time is not enough to measure favorable changes in many endocrine symptoms related 
to AI use. However, the intervention described in this study is a 12-month intervention so further 
results will allow for a potentially more meaningful effect of exercise on endocrine symptoms. 




There was no effect of adherence on endocrine-related QOL scores. This may be because 
almost all of the participants attended at least 70% of the gym sessions and exercised 
recreationally for more than 110 minutes per week. While there were no incentives for 
attendance, the women were likely motivated to attend due to the free gym membership and 
personal trainer. With such a small sample size of exercisers it may have been difficult to detect 
a difference by adherence to the study goals due to low statistical power. However, the HOPE 
study described is set to enroll approximately 90 exercisers total which will potentially allow for 
a dose-response relationship with exercise on endocrine-related QOL to be detected. However, 
when stratified by weight loss, there was a significant difference in endocrine-related QOL. It 
may be that weight loss is a good predictor of true adherence to the study exercise goals. 
 A moderately significant effect of exercise was detected on the FACT-B +ES and the 
FACT-B QOL scales. This suggests that exercise may have an impact on overall QOL in breast 
cancer survivors. The FACT-B subscales allow for different aspects of QOL to be examined. A 
significant effect of exercise was seen in particular for the physical well-being and social/family 
well-being subscales. The participants in our study had normal levels of physical well-being for 
women taking AIs at baseline and this value increased over the study period to scores much 
closer to published values for women not undergoing endocrine-therapy[3]. It is well established 
that exercise is associated with more beneficial physical health outcomes, including better 
general and health-related QOL[22]. The participants had high levels of social well-being at 
baseline which increased over the study period for the exercise group. The social subscale may 
have shown a significant effect of exercise due to the social nature of the exercise-trainer 
sessions and the interaction between participants at gym sessions. The participants in our study 
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had high levels of emotional well-being as compared to previous studies of women undergoing 
various types of endocrine therapy so an increase in this measure may not have been seen due to 
the ceiling effect[3]. Although the participants in our study had relatively low scores on the 
breast cancer subscale which increased across the 6 month intervention period, a significant 
difference was not seen between the two groups (though the increase for the exercise group was 
2-fold higher than the usual care group); however, a significant difference may be seen with a 
larger sample size. 
One limitation of this study is that we did not screen on FACT-B-ES so there may be 
women who already had a high or healthy/normal FACT-B-ES at baseline and therefore no 
change was able to be observed. However, we did screen on other AI side effects, (i.e., 
arthralgias, pain/stiffness). Compared to other studies looking at FACT-B and FACT-B-ES QOL 
scales for breast cancer survivors currently taking AIs, the women in this study had lower scores 
for both measures[3]. The QOL scores for the women in this study were also lower than 
published values for breast cancer survivors not undergoing endocrine therapy. The endocrine 
subscale for women in our study had an average score of 55.2 (S.D. 8.9) at baseline compared to 
published values of 62.4 (S.D. 7.4) for women taking AIs, but not necessarily experiencing side 
effects, and 61.1 (S.D. 10.5) for women not taking AIs[3]. Given that this sample does have 
some adverse AI side effects, it is reasonable and somewhat expected that they had a lower or 
impaired FACT-B-ES as compared to breast cancer survivors undergoing endocrine therapy with 
AIs who may or may not be experiencing pain associated with AI use. 
This is the first study to examine the effect of exercise specifically on endocrine-related 
QOL. Other studies have used various approaches to improving endocrine symptoms in breast 
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cancer survivors including mindfulness-based stress reduction[23], acupuncture[24], physical 
therapy, and targeted heat[18]. Pharmacological therapies such as use of non-steroidal anti-
inflammatory drugs (NSAIDS), cyclooxygenase-2 (COX-2) inhibitors, glucosamine, and 
narcotic analgesics have also been studied but may be contraindicated or ineffective[18]. None of 
these non-pharmacological or pharmacological therapies have been shown to sufficiently 
effective in alleviating symptoms. Therefore, there is a strong need to develop better therapies to 
improve endocrine symptoms. 
New joint symptoms/pain or vasomotor symptoms, which are common with AI endocrine 
therapy, are an indicator of more beneficial treatment outcomes including breast cancer 
recurrence[25]. While the reasoning is not fully understood, this provides strong evidence for the 
need for beneficial interventions that can improve these symptoms which are worse in women 
who may benefit the most from AI treatment. Further research is needed to better understand 
why some women experience worse symptoms than others and the role of exercise in alleviating 
these adverse symptoms to increase adherence to endocrine therapy.  
Conclusions 
Given the effectiveness of AIs in improving risk of recurrence and breast cancer death, 
and the resulting strong recommendation by clinicians for their patients to take AIs, 
understanding how to decrease the severity of AI side effects is necessary. Since side effects 
associated with AI use are quite common and this is the main reason for treatment 
discontinuation, this innovative non-pharmacologic intervention could benefit a large number of 
breast cancer survivors and increase the successful implementation of AIs in breast cancer 
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treatment. In our study, favorable changes in certain endocrine-related quality of life symptoms 
were observed. The effect of exercise on these symptoms is promising for breast cancer 
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Below is a list of statements that other people with cancer have said are important to their quality 
of life.  Please indicate the extent to which you have experienced each of the statements during 
the past 7 days by circling the appropriate number using the following scale. 
                   0                     1                       2                       3                      4 
                         not at all          a little bit         somewhat        quite a bit       very much 
 
During the PAST WEEK: 
 
PHYSICAL WELL - BEING 
 1. I have a lack of energy.     0 1 2 3          4 
 
 2. I have nausea.      0 1 2 3          4 
 
 3. Because of my physical condition, I have trouble  0 1 2 3          4 
     meeting the needs of my family. 
 
 4. I have pain.      0 1 2 3          4 
 
 5. I am bothered by side effects of treatment.  0 1 2 3          4 
 
 6. I feel sick.     0 1 2 3          4 
 
 7. I am forced to spend time in bed.    0 1 2 3          4 
 
SOCIAL/FAMILY WELL - BEING 
 8. I feel close to my friends.     0 1 2 3          4 
 
 9. I get emotional support from my family.   0 1 2 3          4 
 
10. I get support from my friends.    0 1 2 3          4 
 
11. My family has accepted my illness.   0 1 2 3          4 
 
12. I am satisfied with family communication about  0 1 2 3          4 
      my illness.        
 
13. I feel close to my partner (or the person who is  0 1 2 3          4 
      my main support). 
 




During the PAST WEEK: 
EMOTIONAL WELL - BEING 
 
15. I feel sad.       0 1 2 3          4 
 
16. I am satisfied with how I am coping with my illness. 0 1 2 3          4 
 
17. I am losing hope in the fight against my illness.  0 1 2 3          4 
 
18. I feel nervous.      0 1 2 3          4 
 
19. I worry about dying.     0 1 2 3          4 
 
20. I worry that my condition will get worse. 0 1 2 3          4 
 
 
FUNCTIONAL WELL - BEING 
 
21. I am able to work (include work at home).  0 1 2 3          4 
 
22. My work (include work at home) is fulfilling.  0 1 2 3          4 
 
23. I am able to enjoy life.    0 1 2 3          4 
 
24. I have accepted my illness.    0 1 2 3          4 
 
25. I am sleeping well.     0 1 2 3          4 
 
26. I am enjoying the things I usually do for fun.  0 1 2 3          4 
 
27. I am content with the quality of my life right now. 0 1 2 3          4
27 
 




28. I have been short of breath.    0 1 2 3          4 
 
29. I am self-conscious about the way I dress.  0 1 2 3          4 
 
30. My arms are swollen or tender.    0 1 2 3          4 
 
31. I feel sexually attractive.     0 1 2 3          4 
 
32. I have been bothered by hair loss.   0 1 2 3          4 
 
33. I worry about the risk of cancer in my family.  0 1 2 3          4 
 
34. I worry about the effect of stress on my illness.  0 1 2 3          4 
 
35. I am bothered by a change in weight.   0 1 2 3          4 
 







Table 1: Endocrine Subscale for the FACT-B 
Please indicate how true each statement has been for you during the past 7 days 








I have hot flushes 
I have cold sweats 
















I have vaginal discharge 0 1 2 3 4 
I have vaginal itching/irritation 0 1 2 3 4 
I have vaginal bleeding or spotting 0 1 2 3 4 
I have vaginal dryness 0 1 2 3 4 
I have pain or discomfort with intercourse 0 1 2 3 4 
I have lost interest in sex 0 1 2 3 4 
I have gained weight 0 1 2 3 4 
I feel lightheaded/dizzy 0 1 2 3 4 
I have been vomiting 0 1 2 3 4 
I have diarrhea 0 1 2 3 4 
I get headaches 
I feel bloated 
I have breast sensitivity/tenderness 
I have mood swings 
I am irritable 

















































   Non-Hispanic white 81.0 94.4 
   African-American 






   Less than High School graduate 
   High School graduate 
   Some school after high school 











Time since diagnosis (y) 
Disease stage (%) 
   Stage I 
   Stage II 
   Stage III 
   Unknown 
Treatment (%) 
   None 
   Radiation only 
   Chemotherapy only 
   Radiation and chemotherapy 



































   (min/wk recreational exercise) 




   (min/wk recreational exercise) 
52.1 (72.3) 75.4 (105.7) 
No statistically significant differences between exercise and usual care groups at baseline. 
1
Mean min/week of moderate- to vigorous-intensity sports/recreational physical activity as 
determined from the baseline physical activity questionnaire that assessed activity levels for 6 
months prior to study enrollment 
2
Mean min/week of moderate- to vigorous-intensity sports/recreational physical activity at 




Table 3: Adherence from baseline to 6-months in the HOPE study (N=39) 




Mean (SD) 135 (71.9) 
 
% of goal 90% 
% of subjects adhering to  
 
 
≥ 150 min/week (100%) 43% 
 
≥ 120 min/week (80%) 57% 
 
≥ 90 min/week (60%) 76% 
 
≥ 60 min/week (40%) 91% 






































Change from baseline to 6 months 
 
Breast Cancer Subscale 
Baseline 
6 months 
Change from baseline to 6 months 
 
FACT-B + ES 
Baseline 
6 months 




































































































































Hot flashes 0.2500 0.3889 0.72 
 
Cold sweats 0.2381 0.2222 0.97 
 
Night sweats 0.0476 0.3889 0.30 




Lightheaded/dizziness -0.0476 0.2222 0.31 
 
Headaches 0.0476 0.0556 0.97 
 
Mood swings 0.2857 0.5000 0.47 
 
Irritableness 0.3810 0.3333 0.89 




Weight gain 0.5714 0.5556 0.97 
 
Vomiting 0 0 n/a 
 
Diarrhea -0.0952 0.0556 0.39 
 
Bloating 0.5238 0 0.055 




Vaginal discharge -0.1429 0 0.43 
 
Vaginal itching/irritation -0.0476 -0.2222 0.52 
 
Vaginal bleeding 0 0 n/a 
 
Vaginal dryness 0.2857 -.4444 0.024 
 
Discomfort during intercourse -0.2000 -0.0588 0.71 
 
Loss of interest in sex -0.1905 0 0.73 
 
Breast sensitivity/tenderness 0.1429 -0.3333 0.17 
    Other 
     Joint pain 1.0476 0.2778 0.014 
 
 
